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Introduction
During an episode of critical illness a number of signi-
ﬁ cant changes occur in the microbiota of the human gut. 
Th ese changes occur due to alterations in the stress hor-
mone proﬁ le, impairment of blood supply to the gut, 
immunosuppression, antibiotic use and nutrient deﬁ ci-
ency [1]. In experimental models these changes have 
been shown to occur within 6 to 8 hours, with endoge-
nous Lactobacillus strains being replaced by pathogenic 
bacteria [2]. Th is change can lead to a breakdown in the 
intestinal barrier function that is likely to play a signi-
ﬁ cant role in the pathogenesis of multiple organ dysfunc-
tion syndrome [3,4].
Redressing this balance and exploiting the beneﬁ cial 
eﬀ ects of probiotic bacteria is understandably an area of 
considerable interest. However, the mechanisms by which 
these microorganisms exert their eﬀ ects are various and 
depend upon the dose used, the route(s) of administration 
and the dosing frequency [5]. Furthermore, a number of 
these eﬀ ects are strain speciﬁ c.
Probiotics, prebiotics and synbiotics
Probiotics are deﬁ ned as ‘live microorganisms that confer 
a health beneﬁ t on the host when administered in 
adequate amounts’ [6]. Prebiotics are nondigestible food 
components that stimulate the growth and/or activity of 
bacteria in the digestive tract in ways that may be 
beneﬁ cial to health [7]. Synbiotics are a combination of 
probiotics and prebiotics. Th ere has been an explosion of 
interest in probiotics and their potential health beneﬁ ts 
since 2000, with initial attention focusing on the gastro-
intestinal tract.
Probiotics and the gastrointestinal tract
Th e human intestine is home to hundreds of species of 
bacteria, archaea and eukarya, many of which are non-
culturable but can now be identiﬁ ed using metagenomic 
approaches. Th e bacterial load tends to be highest in the 
large intestine (up to 1011 colony-forming units/g), and 
while the healthy human gut is dominated by Bacteroides, 
Firmicutes and Actino bacteria, each individual has their 
own distinct stool bacterial composition determined by 
environmental and genetic factors. Th is bacterial proﬁ le 
remains relatively constant over time unless altered by 
disease state or antibacterial treatment [8,9].
Culture-based and molecular detection methods have 
demonstrated that it is possible to signiﬁ cantly alter the 
composition of gut ﬂ ora in adults and infants by treat-
ment with probiotics. Sepp and colleagues treated 15 
neonates with Lactobacillus rhamnosus GG for the ﬁ rst 
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2  weeks of life. Th ey found that L.  rhamnosus GG 
persisted for 1  month in eight of these neonates. Th ere 
were also signiﬁ cant diﬀ erences in the bacterial compo-
sition of the stool compared with the control group, with 
increased numbers of coliforms, lacto bacilli and Biﬁ do-
bacterium spp. [10]. Benno and colleagues demonstrated a 
statistically signiﬁ cant increase in biﬁ dobacteria in adults 
treated with L. rhamnosus GG for a 4-week period. Th ey 
also found an increase in lactobacilli and a decrease in the 
proportion of Clostridium spp. [11]. As these techniques 
are based on faecal proﬁ ling, they tend to reﬂ ect the large 
bowel bacterial composition with little information being 
available on the small bowel eﬀ ects of probiotics.
Mechanisms of action of probiotics
Much of the information available on the mechanisms of 
action of probiotics is obtained from animal work and in 
vitro studies; hence we must be careful in extrapolating 
this to humans. What is clear, however, is that there are 
multiple mechanisms by which diﬀ erent probiotic bacteria 
exert their eﬀ ects, and these eﬀ ects may vary with the 
strain and population studied. Table  1 summarises the 
main mechanisms by which probiotics exert their eﬀ ects, 
and Table 2 presents details of commonly used probiotic 
preparations.
Probiotics may alter the local environment within the 
lumen of the gut, producing antimicrobial eﬀ ects on 
pathogenic organisms. Lactic acid-producing and acetic 
acid-producing probiotics reduce the luminal pH result-
ing in an unfavourable milieu for pathogens. Th is has 
been demonstrated in vitro with pathogen growth being 
reduced in a pH-dependent manner by Lacto bacillus spp. 
[12]. Venturi and colleagues demonstrated a signiﬁ cant 
reduction of luminal pH in vivo in ulcerative colitis 
patients treated with the probiotic mixture VSL#3 [13].
Probiotics also exert a direct antimicrobial eﬀ ect via 
the production of bacteriocins. Bacteriocins are proteins 
produced by bacteria that inhibit the growth and 
virulence of other pathogenic bacteria. Probiotic bacteria 
deﬁ cient in the bacteriocin gene are less eﬀ ective pro-
biotics, as demonstrated in a murine model where a 
mutant form of Lactobacillus salivarius UCC118 failed to 
protect against infection with Listeria monocytogenes 
[14]. A wide variety of bacteriocins is recognised, and 
their spectrum of action ranges from antagonism of 
similar bacterial strains to the inhibition of a wide range 
of Gram-positives, Gram-negatives, yeasts and moulds 
[15]. One such example of a broad-spectrum bacteriocin 
is that produced by a subspecies of L.  salivarius. Th e 
ABP-118 bacteriocin inhibits Bacillus, Staphylococcus, 
Enterococcus, Listeria and Salmonella spp. [16].
Bacteria communicate with each other using a mecha-
nism known as quorum sensing. Th is involves the pro-
duc tion and secretion of signalling molecules known as 
autoinducers. In their in vitro study, Medellin-Peña and 
colleagues demonstrated that Lactobacillus acidophilus 
La-5 secretes molecules that disrupt this interbacterial 
communication, reducing expression of virulence-related 
genes by Escherichia coli O157:H7 [17].
Probiotics have also been demonstrated to enhance 
intestinal barrier function. Intestinal barrier function is 
complex and its control involves cellular stability at a 
cytoskeletal and tight junction level, as well as mucus, 
chloride and water secretion. Probiotics have been shown 
to exert an eﬀ ect, in vitro and in vivo, via these 
mechanisms [15]. For example, Lactobacillus plantarum 
299v can enhance mucus production and secretion in 
human intestinal epithelial cells [18]. Th e probiotic strain 
E.  coli Nissle 1917 appears to enhance mucosal barrier 
function by production of human β-defensin 2 [15]. 
E. coli Nissle has also has been demonstrated in vitro to 
reduce adhesion and invasion of intestinal epithelial cells 
by an entero invasive E. coli.
In addition, by competing with pathogens for nutrients 
and adhesion in a microbiological niche, probiotics can 
prevent replication by pathogens, a phenomenon known 
as colonisation resistance [5]. Probiotics can thus pro-
mote the integrity of the gut defence barrier and create 
an unfavourable environment for pathogen colonisation.
Probiotics can also exert a range of immunological 
eﬀ ects. Th e interaction between the luminal bacteria and 
the underlying epithelial and mucosal lymphoid cells is 
referred to as bacterial–epithelial cross-talk. Th is cross-
talk enables probiotics to have an eﬀ ect on both the 
innate and adaptive host immune system [19] – for 
example, promotion of B cells into plasma cells, increased 
production of secretory immunoglobulin A and preven-
tion of activation of the proinﬂ ammatory nuclear trans-
crip tion factor NF-κB [5]. Other immunologic mecha-
nisms include altera tion of the cytokine proﬁ le and activa-
tion of macrophages to present antigen to B lympho cytes 
and increase immuno globulin production [20].
Probiotics in the critically ill
Th e eﬃ  ciency of intestinal barrier function is demon-
strated by the fact that the faecal bacterial concentration 
approaches 1012 organisms/ml in the caecum, while tissues 
one cell deep to the intact intestinal mucosa are usually 
sterile [21]. Any signiﬁ cant insult to the gut or alteration to 
its microbiota is likely to play a role in promoting systemic 
inﬂ ammation and infection in the critically ill population 
[22]. In contrast to the large bowel, the stomach, 
duodenum and jejunum have a relative paucity of bacteria 
(103 to 104 organisms/ml). Th e presence of enteric 
organisms in gastric aspirates is therefore abnormal and 
represents gastric colonisation. In the context of critical 
illness, this colonisation is the result of bacterial 
overgrowth in the proximal gastro intestinal tract [21].
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Colonisation of the stomach by pathogens or potential 
pathogens is believed to occur due to a combination of 
poor gut motility, increased gastric pH (due to acid 
suppression) and the use of broad-spectrum antibiotics. 
Th is combination of factors leads to an overgrowth of 
bacteria in the duodenum, which reﬂ ux into the stomach 
and are ultimately regurgitated and aspirated into the 
lungs [23].
Th e normal intestinal microbiota of critically ill patients 
is altered and replaced by pathogens for a number of 
reasons. Th erefore, it would seem logical to consider that 
probiotics may have a role in reducing intestinal 
Table 1. Summary of mechanisms of action for probiotics
Mechanism of action Specifi c probiotic examples
Luminal pH modifi cation Production of lactic acid and acetic acid reduces 
luminal pH resulting in unfavourable milieu for 
pathogens
Lactobacillus spp.: pH-dependent reduction in pathogen growth [12]
VSL#3: in vivo luminal pH reduction in ulcerative colitis patients [13]
Bacteriocin production Bacteriocins are proteins produced by bacteria 
that inhibit the growth and virulence of other 
microorganisms. The may be narrow spectrum (inhibit 
related bacterial strains) or broad spectrum (inhibit a 
wide range of bacteria, yeasts and moulds) [15]
Mutant Lactobacillus salivarius defi cient in bacteriocin gene are unable to 
protect mice against Listeria monocytogenes infection [14]
L. salivarius subspecies produce broad-spectrum bacteriocins [16]
Disruption of 
interbacterial 
communication
Autoinducers are the signalling molecules produced 
and secreted by bacteria that form the basis of 
quorum sensing (bacterial communication)
Lactobacillus acidophilus La-5 disrupts quorum sensing and expression of 
virulence-related genes by Escherichia coli O157:H7 [17]
Enhanced mucosal 
barrier function
Increased intestinal epithelial cell mucus production 
and secretion
Reduced adhesion and invasion of intestinal epithelial 
cells by enteroinvasive bacteria resulting in reduced 
translocation
Increased production of human β-defensin 2 by 
epithelial cells
Stabilisation of intracellular tight junctions and 
reduced chloride/water secretion
Epithelial cell regeneration and reduced apoptosis
Lactobacillus plantarum 299v: increased mucin gene expression in vitro 
[18] and adherence to colonic cells via a mannose-specifi c adherence 
mechanism [74]
Lactobacillus casei rhamnosus adheres to colonic cells in vitro [75]
E. coli Nissle 1917: increase in mucin gene expression [76] and production 
of human β-defensin 2 by colonic cells [77]
Streptococcus thermophiles and L. acidophilus reduce water and chloride 
secretion in response to pathogenic bacteria [78,79]
Lactobacillus pretreatment of intestinal epithelium reduces disruption of 
epithelial tight junctions by pathogenic E. coli [80]. Probiotic preparation 
VSL#3 (see Table 2) prevents redistribution of epithelial tight junction 
proteins on exposure to pathogenic bacteria [76]. Lactobacillus rhamnosus 
GG prevents cytokine-mediated apoptosis of intestinal epithelial cells [81]. 
Lactobacillus casei and Clostridium butyricum both stimulate gut epithelial 
proliferation in rats [82]
Colonisation resistance The probiotic competes with pathogen for nutrients 
and adhesion in a microbiological niche [5]
L. casei rhamnosus adheres to colonic cells, reduces pathogenic bacterial 
growth and can persist within the gastrointestinal tract [75,83]
E. coli Nissle 1917 inhibits growth of Shiga-toxin producing E. coli [84]
Immunological eff ects Bacterial–epithelial cross-talk enables luminal 
probiotic organisms to infl uence gut-associated 
lymphoid tissue and innate and adaptive host 
responses [19,85]. Toll-like receptors play a central role 
in mediating this process [86]
Increased promotion of B cells to plasma cells and 
increased production of immunoglobulins [5]
Activation and modulation of macrophages, T cells 
and natural killer cells
VSL#3 has been associated with increased anti-infl ammatory and reduced 
proinfl ammatory cytokine activity, reduced inducible nitric oxide synthase 
and matrix metalloproteinase activity in patients with pouchitis [87]. 
L. plantarum 299v increases IL-10 secretion from macrophages and T cells 
in patients with ulcerative colitis [88]. L. casei and Lactobacillus bulgaricus 
signifi cantly reduce TNFα release from infl amed mucosa in Crohn’s disease 
[89]. E. coli Nissle 1917 shows local and systemic anti-infl ammatory eff ects 
in a murine model of lipopolysaccharide-induced sepsis [90]
L. rhamnosus GG: increased circulating IgA, IgG and IgM concentrations in 
children with gastroenteritis [91,92]. Pretreatment with probiotic prior to 
typhoid vaccination leads to increased anti-typhoid antibody titres [93]
L. casei Shirota: cell wall structure potently induces IL-12 production and 
the probiotic diff erentially controls the infl ammatory cytokine responses 
of macrophages, T cells and natural killer cells [30,94,95]. L. casei Shirota 
and Bifi dobacterium breve administered preoperatively to biliary cancer 
patients signifi cantly reduce postoperative IL-6, C-reactive protein and 
white cell count concentrations [30]. L. acidophilus and Bifi dobacterium 
longum increased macrophage phagocytic activity in a murine model [96]
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colonisation by pathogens and thus in the prevention of 
infection and sepsis syndromes in this population.
Probiotics in the prevention of nonrespiratory 
infection
Probiotics have been studied in the prevention of post-
operative infection. Th ree studies in patients undergoing 
major colorectal surgery have shown no signiﬁ cant 
reduc tion in postoperative infection rates [24-26]. In 
each study, however, the eﬀ ectiveness may have been 
limited by a relatively short postoperative period of 
probiotic administration (4 to 5 days). In contrast, several 
studies in patients undergoing pancreatic resection [27,28] 
and hepatic resection [29,30] have shown signiﬁ cant 
reduc tions in postoperative infection rates of up to 30%. 
Th ese patients received probiotic for 8 to 14 days 
post operatively.
Liver transplant patients have multiple risk factors for 
infection, including profound immunosuppression. Two 
randomised trials have shown probiotics to be safe and 
eﬀ ective in this group of patients. In the ﬁ rst study 95 
patients were randomised to receive standard enteral 
feed plus selective bowel decontamination, ﬁ bre-contain-
ing enteral feed plus live L.  plantarum 299 (Lp299) or 
ﬁ bre-containing enteral feed plus heat-killed Lp299 [31]. 
Th e live Lp299 group developed signiﬁ cantly fewer infec-
tions than the other two groups (48% vs. 13% vs. 34%, 
respectively). In addition, the mean duration of antibiotic 
Table 2. Summary of probiotic preparations
Probiotic Constituents Administration example and dosing comments
Antibiophilus (Lcr35) 
(Germania Pharmazeutika GesmbH, 
Vienna, Austria)
Lactobacillus casei rhamnosus 109 CFU twice daily via nasogastric tube [75]
Ecologic 641 
(Winclove Bio Industries, 
Amsterdam, the Netherlands)
Six diff erent strains of bacteria: Lactobacillus 
acidophilus, Lactobacillus casei, Lactobacillus 
salivarius, Lactococcus lactis, Bifi dobacterium 
bifi dum, and Bifi dobacterium lactis (previously 
classifi ed as Bifi dobacterium infantis), plus 
cornstarch and maltodextrins
Administered twice daily via nasojejunal tube to a total daily 
dose of 1010 bacteria [35]
Ergyphilus 
(Nutergia, Capdenac, France)
Predominantly Lactobacillus rhamnosus GG, but 
also L. casei, L. acidophilus and B. bifi dum
One capsule contains 2×1010 lyophilised bacteria. Capsules can 
be broken and given via enteral feeding tube. Five capsules 
administered over 24 hours in critically ill patients [53]
Mutafl or 
(Ardeypharm GmbH, Herdecke, 
Germany)
Escherichia coli Nissle 1917 2.5×109 to 25×109 bacteria per capsule. Adult dose 1 or 2 
capsules per day [97]
Proviva 
(Skanemejerier, Malmo, Sweden)
Lactobacillus plantarum 299v and oatmeal Oatmeal-based drink containing 5×107 CFU/ml. Dose of 500 ml 
used by McNaught and colleagues [24]
Synbiotic 2000 (Medipharm, 
Kagerod, Sweden 
and Des Moines, IA, USA)
A probiotic mixture comprising Pediacoccus 
pentosaceus 5-33:3, Leuconostoc mesenteroides 
77:1, Lactobacillus paracasei ssp., paracasei F19, 
L. plantarum 2362 plus β-glucan, inulin, pectin and 
resistant starch
Administered twice daily via feeding tube or orally [32]
Synbiotic 2000 Forte 
(Medipharm, Kagerod, Sweden 
and Des Moines, IA, USA)
A probiotic mixture comprising P. pentosaceus 
5–33:3, L. mesenteroides 32–77:1, L. paracasei ssp. 
paracasei 19 and L. plantarum 2362, plus inulin, oat 
bran, pectin and resistant starch
Sachet for reconstitution containing 1010 each bacteria plus 10 g 
prebiotic fi bre. Administered in doses of 12 g (1 sachet) per day 
for a 15-day study period [47]
Trevis 
(Christen Hansen, Hørsholm, Denmark)
L. acidophilus La5, Lactobacillus bulgaricus, B. lactis 
Bb-12 and Streptococcus thermophilus
4×109 CFU/capsule. One capsule three times daily [25,26]
VSL#3 
(Ferring Pharmaceuticals, 
West Drayton, UK)
Four strains of Lactobacillus (L. acidophilus, L. casei, 
L. plantarum, Lactobacillus delbrueckii), three strains 
of Bifi dobacterium (B. infantis, Bifi dobacterium 
longum, Bifi dobacterium breve) and one strain of 
Streptococcus salivarius subsp. Thermophilus
Powder for reconstitution with water or to be mixed with cold 
foods prior to consumption. One sachet contains 4.5×1011 lactic 
acid bacteria. Also available as a capsule containing 2.25×1011 
bacteria
Adult dose 0.5 to 8 sachets (2 to 32 capsules) per day depending 
upon disease activity. Six grams once a day for 12 months 
administered by Venturi and colleagues [13]
CFU, colony-forming units.
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therapy, the mean total hospital stay and the length of 
ICU stay were also shorter than in the groups with 
inactivated Lp299 and selective bowel decontamination. 
However, these diﬀ erences did not reach statistical 
signiﬁ cance. Th e second study compared only Synbiotic 
2000 and prebiotic ﬁ bre, reporting postoperative infec-
tion rates of 3% and 48%, respectively [32]. No serious 
side eﬀ ects or infec tions caused by the probiotics were 
noted in either study.
Oláh and colleagues randomised 45 patients with 
severe acute pancreatitis to receive enteral oat ﬁ bre and 
live Lp299 or enteral oat ﬁ bre and heat-killed Lp299 [33]. 
In the group treated with the live probiotic, only one 
patient required surgery for a septic complication involv-
ing the pancreas, compared with seven such compli ca-
tions in the control group (P  =  0.02). Th ere was also a 
nonsigniﬁ cant trend toward a shorter length of hospital 
stay (13.7  days vs. 21.4  days, respectively). Th e same 
group carried out a single-centre, double-blind, random-
ised placebo-controlled trial using Synbiotic 2000 in a 
further 62 patients with severe acute pancreatitis [34]. 
Th is trial showed no statistically signiﬁ cant diﬀ erences in 
the incidence of mortality, septic complications or 
develop ment of multiorgan failure between the two 
groups. However, the total incidence of systemic inﬂ am-
ma tory response syndrome, multiple organ failure and 
rate of complications was signiﬁ cantly less in the treat-
ment group versus the control group (8 vs. 14, P  <0.05 
and P <0.05, respectively).
Th e trial that has raised most concern with regard to 
adverse outcomes and the use of probiotics is the 
PROPATRIA trial [35]. In this multicentre, placebo-
controlled trial, 296 patients with predicted severe acute 
pancreatitis were randomised to receive the synbiotic 
preparation Ecologic 641 or placebo. Th is was adminis-
tered together with ﬁ bre-enriched enteral feed via the 
nasojejunal route for 28 days. Th e rate of infectious com-
plications was similar in both groups (30% vs. 28%) but 
the mortality rate was higher in the synbiotic group. Nine 
patients in the synbiotic group developed bowel 
ischaemia, eight of these being small bowel ischaemia. 
Th ere were no cases of bowel ischaemia in the placebo 
group. One possible explanation for this outcome is a 
diﬀ erence in the two groups, with more patients in the 
synbiotic group having established organ failure at the 
time treatment began. Another theory is that such a 
signiﬁ  cant intestinal burden of bacteria and high-ﬁ bre 
feed could result in increased oxygen consumption and 
local bowel ischaemia. Nevertheless, this is the ﬁ rst time 
such a complication has been reported.
Probiotics in the prevention of respiratory infection
Th e respiratory tract is consistently the most common 
site of nosocomial infection, accounting for 65% of 
ICU-acquired infections [36]. Ventilator-associated 
pneu monia (VAP) complicates the care of up to 30% of 
patients receiving mechanical ventilation, accounting for 
50 to 60% of total antibiotic days [37-40]. Patients with 
VAP present increased morbidity and mortality, 
prolonged ICU and hospital lengths of stay, and increased 
costs [41].
Current VAP prevention strategies aim to reduce 
colonisation of the oropharynx and upper gastrointestinal 
tract with pathogenic bacteria and prevent their subse-
quent aspiration. Th ese measures include elevation of the 
head of the bed, silver-coated tracheal tubes, oral care, 
subglottic secretion drainage and use of sedation breaks 
and weaning protocols. Selective digestive tract deconta-
mi nation using antibiotics in the oral cavity or whole 
gastrointestinal tract decontamination have been shown 
to reduce rates of VAP and mortality [42,43]. However, 
these strategies have not gained widespread favour in 
critical care owing to concerns about promoting 
antibiotic resistance. Oostdijk’s group demonstrated a 
statistically signiﬁ cant increase in intestinal colonisation 
with Gram-negative bacteria resistant to ceftazidime, 
tobra mycin or cipro ﬂ oxacin (P <0.05) [44]. Th ese con-
cerns were also borne out by a large-cluster, randomised 
cross-over study of selective decontami nation of the 
digestive tract that showed a marked increase resistance 
to ceftazidime in faecal Entero bacteriaceae, together with 
a small but signiﬁ  cant increase in bacterial resistance 
from the respiratory tract [45]. In a previous study, the 
use of cefotaxime as part of selective decontamination of 
the digestive tract regime was found to select for an 
outbreak of extended-spectrum β-lactamase-producing 
E. coli and Klebsiella pneumonia [46].
To date there have been eight randomised controlled 
trials of probiotic therapy as a strategy to prevent VAP 
[38,47-53]. Th e inclusion criteria, sample size (range 50 
to 348), populations studied and diagnostic criteria for 
VAP varied between studies. Th e probiotic formula, 
dosing and route of administration also varied but all 
trials contained Lactobacillus spp. (see Table  3). Six of 
the eight trials showed a lower incidence of VAP in the 
probiotic group [38,47,48,50–52], but this diﬀ erence was 
statistically signiﬁ cant in only three of the studies 
[38,47,48]. Interestingly, one study used chlorhexidine 
oral disinfection as a control and found that probiotic 
Lp299 was at least as eﬀ ective in preventing oropharyn-
geal colonisation (61.9% vs. 34.8% new colonisation, 
respect ively; P  =  0.13) [50]. Th e study by Forestier and 
colleagues found no diﬀ erence in incidence of VAP 
between groups but did demonstrate a median delay in 
respiratory colonisation with Pseudomonas aeruginosa of 
50 days versus 11 days in controls (P = 0.01) [49]. Th is is 
the most commonly isolated antibiotic-resistant Gram-
negative species in VAP [39].
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Conﬂ icting results also arise from meta-analyses of 
probiotics in critical care. Th e work by Watkinson and 
colleagues in 2007 analysed the use of prebiotics, pro-
biotics and synbiotics in 999 adult critical care patients 
from eight randomised controlled trials and concluded 
that there was no beneﬁ t in the probiotic prophylaxis of 
VAP [54]. In 2010, however, Siempos and colleagues 
examined ﬁ ve randomised controlled trials (689 patients) 
and showed that probiotic administration was associated 
with a lower incidence of VAP when compared with 
standard care (odds ratio = 0.61; 95% conﬁ dence interval = 
0.31 to 0.91) [55]. Importantly, both of these were 
published before the studies by Morrow and colleagues 
[38], Oudhuis and colleagues [52] and Barraud and 
colleagues [52].
Th e trial by Morrow and colleagues is unique in that it 
included oropharyngeal slurry as one of the routes of 
administration for the probiotic [38]. Th e research group 
randomised 146 ventilated patients who were considered 
at high risk for VAP to receive probiotic L.  rhamnosus 
GG or placebo (inulin) within 24 hours of intubation 
until extubation, tracheostomy or death. Th e primary 
outcome was microbiologically conﬁ rmed VAP based on 
quantitative culture of distal airway samples obtained by 
bronchoscopy. Th e incidence of VAP was signiﬁ cantly 
reduced in the probiotic group (19.1% with probiotic vs. 
40.0% with placebo, P = 0.007).
Morrow and colleagues also examined the incidence of 
Clostridium diﬃ  cile and ICU-associated diarrhoea in 
their patients. Th e probiotic group had signiﬁ cantly less 
C.  diﬃ  cile cytotoxin-positive diarrhoea compared with 
the placebo group (5.6% vs. 18.6%, P = 0.02), although the 
duration of diarrhoea was not signiﬁ cantly lower. How-
ever, patients treated with probiotic received fewer days 
of antibiotics for C.  diﬃ  cile-associated diarrhoea 
(0.5  ±  2.3 days vs. 2.1  ±  4.8  days in placebo group, 
P = 0.02). Th e duration of ICU-associated diarrhoea was 
also signiﬁ  cantly reduced in the probiotic group (4.1 ± 3.7 
days vs. 5.9 ± 3.8 days in placebo group, P = 0.03).
Th e rates of oral colonisation with pathogenic species 
at 72 hours (70% for placebo vs. 38.2% for Lactobacillus, 
P <0.001) correlated with development of VAP (Pearson 
correlation coeﬃ  cient  = 0.22, P  =  0.009). Interestingly, 
the probiotic treatment appeared to preferentially reduce 
rates of infection caused by Gram-negative pathogens 
(22.8% for placebo vs. 8.8% for Lactobacillus, P  =  0.02) 
while having no statistically signiﬁ cant eﬀ ect on Gram-
positive species (12.8% vs. 5.8%, P = 0.16).
To date, studies of probiotics in the critically ill have 
trialled a number of species, Lactobacillus featuring 
frequently. Currently unknown, however, is whether one 
species is superior in the prevention of infection 
associated with critical illness. Similarly, the optimal 
administration route, dosage and duration of treatment 
are not clear. Further research is undoubtedly warranted, 
perhaps considering Gram-negative probiotic species.
Administration of probiotics and monitoring of 
their eff ects
Probiotics are commercially available in various prepara-
tions including yoghurt-based products, capsules, powders 
and suspensions. Th e studies in critically ill patients 
discussed above involve enteral administration of a 
variety of probiotic strains using diﬀ erent dosing regimes.
In eight of the nine studies involving mechanically 
ventilated patients (Table 3), probiotic powder or capsule 
contents were dissolved in water and delivered via a 
feeding tube into the stomach. Morrow and colleagues 
used an oropharyngeal slurry of L.  rhamnosus GG 
(suspended in a sterile water-based surgical lubricant) in 
addition to nasogastric administration [38]. After 
72 hours, the patients receiving this regime were found to 
have lower rates of oral (38.2% vs. 70%, P  =  0.001) and 
gastric (32.3% vs. 45.7%, P  =  0.03) colonisation with 
pathogenic species than those receiving placebo. Klarin 
and colleagues used topical application of Lp299 to the 
oral cavity alone and found it to be at least as eﬀ ective as 
chlorhexidine 0.1% in reducing oropharyngeal patho-
genic load [50].
Testing for colonisation of the gastrointestinal tract 
with the probiotic species is reported in only a minority 
of studies. McNaught and colleagues collected gastric 
aspirates at induction of anaesthesia in elective surgical 
patients who had received at least 1 week of oral Lp299 
[24]. Th e probiotic species was not isolated in any 
subject. In the study by Forestier and colleagues, however, 
gastric aspirates were taken at inclusion, at day 7 and at 
discharge. Lactobacillus casei rhamnosus was detected in 
52 out of 102 patients on probiotic treatment after a 
median of 13  days [49]. In the study by Klarin and 
colleagues described above, the probiotic species Lp299 
was detected in all oropharyngeal cultures and in the 
tracheal cultures from 56% of patients in the probiotic 
arm [50]. Knight and colleagues demonstrated detection 
of probiotic species in stool culture after 3 days treatment 
with Synbiotic 2000 Forte, indicating its survival from the 
stomach to the distal gut [56]. However, they did not 
routinely analyse stool samples in their more recent study 
[51]. None of the other studies cited in Table 3 reported 
detection of probiotic species in any microbiological 
specimens.
Quality and safety
Probiotics are now widely available and are being 
consumed daily in large quantities. Overall they have an 
excellent safety record, but there are some concerns that 
are likely to lead to caution in their widespread use in 
clinical practice.
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Th e availability of diﬀ erent probiotics varies from 
country to country and there can be lack of consistency 
between manufacturers, and even batches, in terms of 
density of bacteria, adhesion characteristics, stability and 
viability [57]. Strain-speciﬁ c adhesion properties and 
viability have been shown to vary between batches from 
the same manufacturer, which could lead to conﬂ icting 
clinical trial results [58].
Th ere have been a number of publications reporting 
serious infections caused by Lactobacillus spp. related to 
those used as probiotics [59]. Th e Finnish group of 
Salminen and colleagues examined 89 cases of Lacto-
bacillus bacteraemia. In 11 cases, the strain was identical 
with the probiotic L. rhamnosus GG [60]. However, they 
could not directly relate these cases to probiotic 
consumption. Salminen and colleagues also examined 
trends in Lactobacillus bacteraemia in Finland over the 
period 1990 to 2000. Th is period coincided with a rapid 
increase in the consumption of probiotic L.  rhamnosus 
GG. Th e group concluded that increased probiotic use 
had not led to an increase in Lactobacillus bacteraemia 
[61].
Th ere are case reports in the literature of Lactobacillus 
infection and bacteraemia that appear to be directly 
related to probiotic consumption [62–65]. All of the 
patients involved were immunocompromised to some 
degree and the causative organism was linked to the 
probiotic by molecular techniques. Infections caused by 
Lactobacillus spp. from probiotics have also been 
reported in immunosuppressed patients – including 
those with acquired immunodeﬁ ciency syndrome and 
those following lung and liver transplantation [66–68]. 
Lactobacillus bacteraemia has been associated with 
structural heart abnormalities, valve prosthesis or prior 
endocarditis [69]. However, the majority of clinical trials 
using Lactobacillus spp. probiotics report few adverse 
eﬀ ects.
Th e only reported infection associated with probiotic 
E. coli Nissle 1917 is in a premature neonate (gestational 
age 28 weeks) [70]. Th e child had an extremely low birth 
weight of 935 g and developed gastroenteritis due to 
rotavirus and adenovirus 14 days into the postnatal 
period. E.  coli Nissle treatment initially led to improve-
ment but the child developed severe sepsis 10 days later 
and subsequently E. coli Nissle 1917 was isolated in blood 
cultures. Th e child was treated with antibiotics and made 
a full recovery.
A wide range of probiotic species is being investigated 
for an increasing number of indications. Th ere has been 
little work carried out on the rationale behind which 
probiotics are used and in what combination. Timmer-
man and colleagues attempted to address this issue by 
examining speciﬁ c strains in an attempt to produce an 
eﬀ ective multispecies mixture [71]. Th e symbiotic 
preparation Ecologic 641 was used in the PROPATRIA 
trial. Th is group selected six strains of Lactobacillus 
based on survival in a simulated gastrointestinal environ-
ment, antimicrobial activity and ability to induce IL-10, 
highlighting the point that there should be a disease-
speciﬁ c rationale for selection of probiotics.
Conclusions
Concerns are mounting about multidrug-resistant Gram-
negative bacteria with the extensive spread of extended-
spectrum β-lactamases [72], and in particular the 
emergence of Enterobacteriaceae with resistance to 
carba penems conferred by metallo-β-lactamase NDM-1 
[73]. New antimicrobial agents with which to tackle 
resistant bacteria are in limited supply, and a recently 
announced EU–US taskforce has called for a commit-
ment to the development of 10 new antibacterial agents 
by 2020. Th is will require a substantial public ﬁ nancial 
investment and will need to be sustained long term 
because continued antibiotic use will maintain the 
pressure on organisms to evolve new resistant strains. In 
the absence of universally eﬀ ective treatments, strategies 
that could prevent the development of ICU-acquired 
infection are needed.
Th e human, animal and in vitro studies of probiotics 
carried out to date exhibit a high level of heterogeneity in 
the conditions targeted, models used and probiotics 
tested. Th ese studies are likely to reﬂ ect an oversimplistic 
view of the mechanisms of action of probiotic species. As 
alluded to above, probiotics are likely to bring about their 
eﬀ ects through multiple processes with diﬀ erent strains 
having very speciﬁ c eﬀ ects.
We are still far from understanding fully the probiotic–
host interaction but, given the potential beneﬁ ts that 
probiotic bacteria have to oﬀ er, further study is 
warranted. Careful consideration should be given to 
further well-powered studies addressing the questions of 
which probiotic by what route, in what dose and at what 
time.
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